Do women have to take post-menopausal hormone therapy after oophorectomy?
Use of low-dose hormone therapy after oophorectomy is controversial. While studies have shown that use of hormone therapy after menopause may increase a woman's risk of breast cancer, other studies suggest early menopause can cause its own serious risks.
Women who undergo prophylactic oophorectomy and don't use hormone therapy up to age 45 have a higher rate of premature death, cancer, heart disease and neurological diseases. For this reason, doctors typically recommend that younger women who have surgically induced menopause should consider taking low-dose hormone therapy for a short time and stop by ages 50 to 52.
It isn't entirely clear what effect hormone therapy might have on your cancer risk. Several studies have found that short-term hormone therapy doesn't increase the risk of breast cancer in women with BRCA mutations who have undergone prophylactic oophorectomy. Ask your doctor about your particular situation. If you decide to take low-dose estrogen, plan to discontinue this treatment after ages 50 to 52.
You may opt to have your uterus removed during your oophorectomy surgery so that you can take a type of hormone therapy (estrogen-only hormone therapy) that may be safer for women with a high risk of breast cancer. Discuss the benefits and risks of hysterectomy with your surgeon.
Are there alternatives to oophorectomy for preventing ovarian cancer?
Researchers are studying other ways to reduce the risk of ovarian cancer in women who have a high risk of the disease. But these other ways of preventing ovarian cancer haven't been proved to reduce risk as much as oophorectomy has. For this reason, for most women with BRCA mutations, doctors recommend oophorectomy.
But oophorectomy isn't right for every woman with a high risk of breast cancer or ovarian cancer. So talk about the alternatives with your doctor to better understand how they may affect your risk. Options include:
Increased screening for ovarian cancer. You may choose to have ovarian cancer screening twice each year to look for early signs of cancer. Screening usually includes a blood test for cancer antigen CA 125 and an ultrasound exam of your ovaries.
In theory, increased screening should be able to help doctors catch ovarian cancer at its earliest stages, but whether that's possible with current screening methods isn't clear. Screening tests are noninvasive, but there's no evidence that they save lives.
Birth control pills. Studies suggest that taking birth control pills reduces the risk of ovarian cancer in average-risk women. There is good evidence that birth control pills can reduce the risk of ovarian cancer and can also be beneficial in reducing risk in high-risk women, such as those with BRCA mutations.
There is some concern that birth control pills may increase the risk of breast cancer in this high-risk group of women. However, the benefits of reducing ovarian cancer risk seem to outweigh the small risk of breast cancer.
Doesn't mastectomy offer a greater reduction in breast cancer risk?
Yes. Surgery to remove your breasts (bilateral mastectomy) may reduce your risk of breast cancer by 90 percent. As an example, if your risk of developing breast cancer at some point in your lifetime is 50 percent, a preventive mastectomy may lower your risk to 5 percent.
Put another way, for every 100 women who underwent preventive mastectomy, 5 could be diagnosed with breast cancer at some point in their lives.
Why might a woman opt for oophorectomy over mastectomy?
Reasons a woman might choose oophorectomy over mastectomy include:
- Oophorectomy reduces your risk of two cancers. Oophorectomy reduces your risk of both breast cancer and ovarian cancer, while mastectomy reduces only the risk of breast cancer.
- There aren't many options for preventing ovarian cancer. Ovarian cancer is sometimes seen as a greater threat than breast cancer because it isn't easily detected, and it may be detected at a later stage when diagnosed. There are tests, such as mammograms and breast MRIs, to detect breast cancer at an early stage in very high-risk women.
- Removing your ovaries doesn't affect your appearance. Some women are concerned about how they'll look if they have their breasts removed. Oophorectomy won't affect your appearance.
These benefits have to be balanced against the risks of oophorectomy and the early menopause that occurs as a result.
What questions should you ask your doctor?
The decision to have prophylactic oophorectomy is a challenging and difficult one with no clearly right or wrong answer. It comes down to a personal choice you alone can make, but advice from a genetic counselor, a breast health specialist or a gynecologic oncologist can help you make a more informed decision.
Questions to ask your doctor or other health care provider include:
- What is my risk of breast cancer?
- What is my risk of ovarian cancer?
- What are my options to lower my risk of breast cancer?
- What are my options to lower my risk of ovarian cancer?
- What are the benefits and risks of each option?
- What are some good sources of information about reducing my cancer risk?
- How much time can I take to research my options and make a decision?
- If I decide that prophylactic oophorectomy isn't right for me right now, can I change my mind later?
- What advice would you give your friend or family member if she were in my situation?
Determining whether prophylactic oophorectomy is right for you — and when it might be right for you — depends on your individual risk of cancer and how aggressive you want to be in your cancer-prevention efforts.
April 14, 2014
See more In-depth
- Muto MG. Risk-reducing salpingo-oophorectomy in women at high risk of epithelial ovarian and fallopian tubal cancer. http://www.uptodate.com/home/index.html. Accessed Nov. 12, 2013.
- Stan DL, et al. Challenging and complex decisions in the management of the BRCA mutation carrier. Journal of Women's Health. 2013;22:825.
- Rebbeck TR, et al. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. Journal of the National Cancer Institute. 2009;101:80.
- Gadducci A, et al. Alternatives to risk-reducing surgery for ovarian cancer. Annals of Oncology. 2013;24(Supp 8):vii47.
- Rocca WA, et al. Premature menopause or early menopause and risk of ischemic stroke. Menopause. 2012;19:272.
- Gierisch JM, et al. Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: A systematic review. Cancer Epidemiology, Biomarkers & Prevention. 2013;22:1931.
- Pruthi S (expert opinion). Mayo Clinic, Rochester, Minn. Nov. 20, 2013.